|
|
|
The value and importance of adult immunisation has generated active debates and discussions over the past year. Now it’s time to hear the latest science and data on vaccine technologies, barriers to immunisation, including hesitancy to vaccinate, and much more.
Five great reasons to register:
 |
Unique opportunity to learn from leading experts from across the globe |
 |
Engagement with the broader vaccine community |
 |
Interactive sessions with international experts |
 |
Certificate of Attendance available per session |
 |
Live & OnDemand available in 8 languages |
|
|
|
        |
Register today to get access to the latest science, presented by top experts
The agenda topics have been selected by an independent Scientific Committee of international experts, providing discussions about trending topics in the vaccine community, with a focus on adult immunisation.
AGENDA:
Day One
March 30th 2022
13:00 - 20:10 CEST |
| • |
Introduction/Keynote/The COVID-19 booster debate: where do we stand today? |
| • |
Breaking news: forgotten issues in vaccines and the concept of One Health |
| • |
Engaging the immunisation neighbourhood – all hands on deck |
| • |
Role of vaccine confidence in adult immunisation and influence of social media/Day One closure |
| |
|
Day Two
March 31st 2022
13:00 - 20:10 CEST |
| • |
Introduction/Keynote/Immunisation of older adults - Part 1: Life course immunisation program and immunosenescene |
| • |
Immunisation of older adults - Part 2: Improving vaccine responses and the role of vaccines in combating antimicrobial resistance |
| • |
Generating momentum around the world to implement adult immunisation |
| • |
Vaccine questions on your mind: ask the expert/Event closure |
Independent Scientific Committee members:
Join the conversation on social media via #VaccineVirtualDays
If you're already registered for Vaccine Virtual Days 2022 event, click below:ALREADY REGISTERED?
This event is organised and funded by GSK and is intended for Healthcare Professionals (HCPs) only. Adverse events reporting:
For HCPs (for physicians and pharmacists) in Belgium, please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use of the Federal Agency for Medicines and Health Products adversedrugreactions@afmps.be or via the ‘yellow card’ available on www.fagg-afmps.be or to GlaxoSmithKline Pharmaceuticals s. a/n.v. +32 010/85 85 00.
For other countries, all HCPs are required to follow their country-specific legal requirements and local guidelines for the reporting of all adverse events https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/ © 2022 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium https://be.gsk.com/en/ Privacy Notice | Terms of Use March 2022 | NX-GBL-GVX-WCNT-210014 Privacy Notice Summary GSK makes every effort to ensure any data you provide is held securely. We will use your data to register you for the event and get your feedback on the quality of the sessions. We will share registrant and attendance information with GSK staff which may include GSK authorised organisers of the event in your country. |
|
Vaccine Virtual Days 2022
Registration Is Closed
|
|
|
|
|